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Immunohistochemical assay was performed for oestrogen receptors (ER) on 
postmastectomy specimens of 66 histologically confirmed cases of primary breast 
carcinoma. All the cases were non-pregnant black African women aged 18 years and 
above and had not had prior anti-cancer therapy. The mastectomy specimens were 
fixed in formal saline and embedded in paraffin wax and subjected to routine 
histopathological procedures. They were graded according to the G-histopathological 
classification. The majority (62.1%) of the tumours were of the G, (moderate) grade. A 
total of 27(65.9%) of them were ER positive. The GI (well differentiated) and G, (poorly 














een the ER status and the 
pathological grade of the 
noma. 
duction 
)w generally accepted that hormone receptor 
is an essential initial step in the management 
east carcinoma patients'. Once established, the 
oqen receptor (ER) status forms the rationale 
: use of endocrine therapy irrespective of 
s' age'.2.3,4,. Until recently, better-differentiated 
carcinomas had been presumed to contain 
er quantities of E R S ~ , ~ ~ ' .  This resulted from 
es based on the Dextrose coated charcoal (DCC) 
technique. From the early 1980s, knowledge of the 
biology of breast carcinoma was revolutionized. A 
carcinoma clone cannot maintain itself if its growth 
factors and /or are blocked8. Breast carcinoma is a 
heterogeneous tumour with regard to hormone 
receptors and growth factors. Oestrogen is 
recognized as a growth factor that interacts with the 
ERs to trigger off the growth of this carcinoma. 
The presence of the ER is therefore advantageous 
to the tumour and not the patients. 
It was in the light of this knowledge that the 
tamoxifen escape phenomenon came to be 
elucidated; the antioestrogens (Tamoxifen, 
Nafoxidine and C1628) cause selective apoptosis of 
only ER +ve cells. Subsequently the tumour becomes 
ER -ve and refractory to tamoxifen9. Compared to 
DCC the immunohistochemical assay (IHA) 
technique is relatively new, much simpler, rapid, 
reproducible, less costly, assesses only the tumour 
cells so that the non-tumour tissue does not pose its 
diluting effect and it can be done o n  routine 
permanent sections including archival ones2."'. It has 
come to replace DCC as the standard procedure of 
ER assayl,ll.~2.13,14 
N o  literature on ER status of black African women 
with breast carcinoma using IHA is availableI5. This 
study was designed to investigate for relationship 
between the ER status and histopathological grade 
of primary breast carcinoma in patients seen with 
the tumour at Mulago Hospital in I<ampala-Uganda. 
The DAKO ID5 IHA monoclonal antibody used 
detected the nuclear E R ' B ~ .  '; exploiting the 
contemporary view that the ER is more permanently 
associated with the n u ~ l e u s ' ~ ~  ". 
Patients and Methods 
The study population consisted of 66 confirmed 
cases of primary breast carcinoma seen between May 
2000 and March 2001 inclusive. All the patients were 
black African women of at least 18 years of age. 
Patients who were pregnant and those who had had 
prior anticancer therapy were excluded from the 
study. 
All the patients subsequently underwent mastectomy. 
About Igrn of formal saline fixed paraffin embedded 
tumour material was obtained from post mastectomy 
specimens of each of these cases. For each one of 
them, the tissue section was cut to about 4m 
thicknesses for immunohistochemical staining and 
routine histology with Haematoxylin and Eosin (H 
& E). 
The indirect immunoperoxidase method was used 
to stain for the ER proteins. 
Sections were deparaffinised and rehydrated in 0.05M 
Tris Buffer Solution p S )  of pH 7.6. Endogenous 
peroxidase activity was inhibited by incubating the 
sections with methanolic 3% Hydrogen peroxide for 
5 L 1 minutes. The primary antibody (dilution 1:50) 
was a supernatant mouse monoclonal antibody to 
the human ER. This antibody belongs to the ID5 
clone and subclass Ig G I  kappa. The  primary 
antibody was incubated at 20 - 25O C for lo+ 1 
minutes. 
After gentle washing with three changes of TBS, the 
sections were incubated for 10 L 1 minutes with 
Streptavidin Biotin Complex (STABC) at a dilution 
of 1:200. STARC contained the secondary antibody. 
This was an antibody against the primary antibody. 
I t  was a biotin labeled goat anti-mouse 
immunoglobulin in a Phospl~ate Buffered Saline 
(PBS) containing a carrier protein. STABC was 
reconstituted prior to use forming a complex with a 
biotinylated secondary antibody. 
The sections were washed again before incubation 
with Diaminobenzidine (DAB) substrate chromogen 
at 20 
- 25°C for 10L 1 minutes to which 0.01% hydrogen 
peroxide was first added immediately before use to 
develop the peroxidase reaction and counterstained 
with Mayers Haematoxylin. Counterstaining was 
done by incubating the specimen at 20 
- 25°C for 2 - 5 minutes. The  slides were 
subsequently dipped in a 37mM ammonia bath and 
rinsed in de-ionized water. The section was then 
dehydrated through increasing concentrations of 
alcohol. A drop of Dextrene Plasticizer in Xylene 
(DPX) was placed on the section. A cover slip was 
then applied to the preparation and allowed to dry. 
Immunohistochemical staining for ER was assessed 
and scored semi-qualitatively by direct light 
microscopy at X 40 objective. Specific staining for 
ER was identified as a reddish-brown end product 
at the site of the target nuclear antigen. A case was 
considered positive if at least 5 of every 100 turnour 
cell nuclei counted per field did pick the stain. 
The IHA reagents were DAB, STABC and the 
primary and secondary antibodies. They were bought 
from the Instut  fiir pathologie Papenbr7-- 
Hamptkanal Links 79-81. 26871 Papenburg, 
DAKO Corporation Agents in Germany. The 
including deionised water, silanized slides, alcc 
DPX were bought locally. A negative control real 
was provided in the DAI<O LSAB @ diagnostic 
It  is a non-human reactive antibody of the 
subclass and animal species as the primary an1 







:kit .  
Statistical Analysis 
Data were summarized descriptively using frequency 
tables and reported as percentages. The Chi-square 
(((2) was used to test for the relationship between 
the ER status and the G-histopathological grade of 
the primary breast carcinoma lesion. The P-value was 
used to test for the statistic significance. 
Results 
The youngest patient was 27 years and the oldest 
one 81 years. Forty-nine (74.2%) of the subjects 
were 51 years or less. 
Routine histology showed that all cases were 
morphologically primary breast carcinoma of various 
grades: well, moderately, and poorly differentiated. 
Immunohistochemical staining showed that 41 
(62.1%) of the 66 cases were ER positive. The 
variation of ER status with grade of breast carcinoma 
was as shown in Table 1. 
Only the epithelial elements were positively stained 
and the staining was in the nuclei. The nuclei with 
ERs stained reddish-brown. A case was considered 
positive if at least 5 of every 100 tumour cell nuclei 
Table 1. ER Status and Grade of Breast Carcinoma 
Chi-square = 1 .I28 P-va lu e = 0.569 
counted per field did pick the stain. The connective were ER negative. Moreover, ER  positivity and 
tissue stroma was not stained. The figures I, 11, I11 negativity were equally represented among the poorly 
and IV show some of the examples of IHA staining differentiated carcinomas. This confirms previous 
for ER and the histopathological grade of the studies that differentiation at tissue or cellular level 
tumour. yields indeterminate information as regards the ER - 
status of the primary breast carcinoma 2 ' . 2 2 n u .  
Discussion 
This study showed a predominance of moderately In conclusion, this study showed that the ER status 
differentiated carcinoma (62.1%); of which 27 was independent of the histopathological grade of 
(65.9%) were ER positive. Fourteen (21.2%) of the the primary breast carcinoma. Therefore, the patient's 
carcinomas were poorly differentiated; half of which ER status should be only determined by ER assay 
were ER positive. Well-differentiated carcinomas and should not  assumed based o n  the 
accounted for 11 (16.7%) of the cases; of which 7 histopathological grade of the primary turnour. 
were ER positive. Of  the ER positive carcinomas 
the majority 27 (65.9%) were moderately Acknowledgement 
differentiated. Of the ER ne~ative carcinomas. 14 We are indebted to I<ULIKA Charitable Trust for 
0 
(56.0°/o) were moderately differentiated. T h e  sponsoring this study. 
relationship between the grade of primary breast 
carcinoma and E R  status was not  statistically 
significant (P-value = 0.569). 
The ER status is an index of biological behaviour 
of primary breast carcinoma 
6*'2. It has become established as a predictor of 
oestrogen hormonal dependence of this tumour"J8. 
Various series using DCC technique have held a 
general agreement that bet ter  differentiated 
carcinomas contain higher quantities of ERs 5*6973'8*19, 
However, the results of this IHA based study showed 
that this may not always be true since an appreciable 
proportion (36.4%) of well-differentiated carcinomas 
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